Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.63Albert David Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company exhibits strong solvency and coverage ratios, indicating a solid financial foundation and the ability to meet its obligations. Profitability, particularly Return on Capital Employed and Return on Equity, reflects reasonable returns, although Return on Assets is low. However, liquidity, efficiency, and growth metrics reveal areas of concern. The company's financial health is further supported by stable book value and dividend payouts. While the company demonstrates strengths in certain areas, addressing the weaknesses in liquidity, efficiency, and growth will be crucial for sustained success.
Health Score : 5.63Albert David Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company exhibits strong solvency and coverage ratios, indicating a solid financial foundation and the ability to meet its obligations. Profitability, particularly Return on Capital Employed and Return on Equity, reflects reasonable returns, although Return on Assets is low. However, liquidity, efficiency, and growth metrics reveal areas of concern. The company's financial health is further supported by stable book value and dividend payouts. While the company demonstrates strengths in certain areas, addressing the weaknesses in liquidity, efficiency, and growth will be crucial for sustained success.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-332.71
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
-333.98
P/B RATIO
1.27
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
1.49
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
33.24
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹871.7 as on Sep 1, 2026.
Growth Score : 2.80The company's growth ratios indicate a mixed performance. While asset growth shows a positive trend, revenue, operating profit, EPS, and net income growth rates are low. This suggests that the company is growing its asset base, but not translating this into increased profitability. The healthcare sector is competitive, and the company needs to focus on strategies to improve its top-line and bottom-line growth.
Revenue Growth RatePoorOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 27.24 | 8.95 | 6.16 | -4.7 | -3.19 |
| Operating Profit Growth Rate | 115.79 | 7.32 | 6.82 | -93.62 | 66.67 |
| Earnings Per Share (EPS) Growth | 59.27 | 2.59 | 108.5 | -77.19 | -108.66 |
| Asset Growth Rate | 17.6 | 5.49 | 17.73 | 2.61 | 1.57 |
| Net Income Growth Rate | 59.09 | 2.86 | 108.33 | -77.33 | -105.88 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 2 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 3 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 4 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 5 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 6 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 7 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 60.35 | Neutral | 7.00 | 1.40 | 4.00 |
| 8 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 9 | BPL Ltd | 5.46 | -28.58 | Neutral | -4.82 | -1.69 | -8.55 |
| 10 | Zim Laboratories Ltd | 5.41 | 108.20 | Neutral | 30.00 | 1.11 | 6.00 |
| 11 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 12 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
| 13 | PANCHSHEEL | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Albert David Ltd. (ADL) is a Kolkata-headquartered Indian pharmaceutical company primarily engaged in manufacturing and marketing a diverse range of pharmaceutical formulations, bulk drugs, and infusions. With a strong presence in various therapeutic segments, the company caters to both domestic and international markets, focusing on quality healthcare products and accessibility.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Albert David Ltd's P/E ratio (TTM) is -332.71, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Albert David Ltd's P/B ratio is 1.27, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Albert David Ltd's P/S ratio is 1.49, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Albert David Ltd's PEG ratio is 0.38.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Albert David Ltd's EV/EBITDA ratio is 33.24.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Albert David Ltd's ROE is -0.26%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Albert David Ltd's ROA is 0.96%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Albert David Ltd's ROCE is 1%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Albert David Ltd's operating margin is 1.50%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Albert David Ltd's net margin is -0.30%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Albert David Ltd's current ratio is 1.23.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Albert David Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Albert David Ltd's interest coverage ratio is 1.33.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Albert David Ltd's DPS is ₹5.01.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Albert David Ltd's EPS is -108.66.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹871.70. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1940
Headquarters: Kolkata, West Bengal
Core Offerings: Pharmaceutical formulations, Bulk drugs (APIs), Infusion products, Nutraceuticals, Consumer products
Stock Listing: NSE (ALBERTDAVD), BSE (524075)
Promoter: N.K. Jalan Group
Albert David Ltd. was incorporated in 1940, establishing itself as an early entrant in the Indian pharmaceutical landscape. Over the decades, the company has expanded its product portfolio across various therapeutic areas, developing both pharmaceutical formulations and active pharmaceutical ingredients (APIs). It has continuously upgraded its manufacturing facilities and strengthened its distribution network, evolving into a diversified healthcare provider with a presence in both domestic and international markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical formulations and bulk drugs | 98.7% | Operating Profit |
| Others | 1.3% | Operating Profit |
Pharmaceutical Formulations: Covers a wide range of therapeutic areas including Gynaecology, Haematopoietic, Gastroenterology, Anti-inflammatory, Anti-infectives, Analgesics, Vitamins, and Neutraceuticals. The company manufactures various dosage forms like tablets, capsules, injectables, liquids, and topical preparations.
Bulk Drugs (APIs): Engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), contributing to backward integration and supply to other pharmaceutical companies.
Infusion Products: Specializes in the production of Intravenous (IV) fluids, essential for critical care and hospital settings.
Mr. Neeraj Kumar Jalan (Managing Director): An experienced professional providing strategic leadership and driving the company's growth and operational excellence in the pharmaceutical sector.
No major subsidiaries reported.
No major recent corporate actions on record.
The Albert David Ltd share price today is ₹871.70 on NSE (ALBERTDAVD), as of 26 Sept 2026.
As of 26 Sept 2026, Albert David Ltd share price is ₹871.70, with previous close ₹871.70. Today's range is ₹871.70 to ₹871.70. The 52-week range is ₹N/A to ₹N/A.
As of today, Albert David Ltd's market cap is ₹496.87 crore (Small Cap).
Albert David Ltd's current P/E ratio is -332.71, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 34.70.
Albert David Ltd's current P/B ratio is 1.27.
Albert David Ltd's current dividend yield is 0.57%. Last dividend of ₹2.50 per share was declared on 23-May-2024.
Albert David Ltd's EPS (TTM) is ₹-108.66.
Albert David Ltd. (ADL) is a Kolkata-headquartered Indian pharmaceutical company primarily engaged in manufacturing and marketing a diverse range of pharmaceutical formulations, bulk drugs, and infusions. With a strong presence in various therapeutic segments, the company caters to both domestic and international markets, focusing on quality healthcare products and accessibility.
Albert David Ltd is promoted by N.K. Jalan Group, holding 62.24% as of 26 Sept 2026.
Albert David Ltd is listed on NSE (ALBERTDAVD) and BSE (524075). Its next quarterly results are expected on August 2024.
